Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.47 |
| ▸ | IKBKB | O14920 | 5/20 | 0.46 |
| ▸ | CHUK | O15111 | 3/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519683 | 0.92 | CDK4 (0.53) | JAK2JAK3ZAP70IKBKBCHUK | |
| SCHEMBL3520531 | 0.88 | SRC (0.52) | JAK2JAK3IKBKBABL1CDK4 | |
| SCHEMBL3518688 | 0.86 | IKBKB (0.63) | JAK2JAK3IKBKBCHUK | |
| SCHEMBL3516442 | 0.82 | CDK2 (0.57) | IKBKBCHUKABL1BCRCDK4 | |
| SCHEMBL3521014 | 0.81 | JAK2 (0.51) | JAK2JAK3ZAP70IKBKBABL1 | |
| SCHEMBL3595329 | 0.80 | IKBKB (0.51) | IKBKBCHUK | |
| SCHEMBL3518636 | 0.80 | JAK2 (0.50) | JAK2JAK3ZAP70IKBKBABL1 | |
| SCHEMBL3520363 | 0.79 | IKBKB (0.48) | JAK2JAK3IKBKBCHUKCCNT1 | |
| SCHEMBL3524787 | 0.78 | IKBKB (0.61) | JAK2JAK3IKBKBCHUKSMG1 | |
| SCHEMBL3516415 | 0.75 | IKBKB (0.59) | IKBKBCDK4CDK2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | JAK2 341/4885JAK3 1251/4885ZAP70 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.